Literature DB >> 10353610

Mutation of the 9q34 gene TSC1 in sporadic bladder cancer.

N Hornigold1, J Devlin, A M Davies, J S Aveyard, T Habuchi, M A Knowles.   

Abstract

Deletions involving chromosome 9 occur in more than 50% of human bladder cancers of all grades and stages. Most involve loss of the whole chromosome or of an entire chromosome arm but some small deletions are found which can be used to define critical regions which may contain tumour suppressor genes. We have localized such a critical region of deletion at 9q34 between the markers D9S149 and D9S66, an interval which contains the Tuberous Sclerosis gene TSC1. Single strand conformation polymorphism (SSCP) and sequence analysis of TSC1 in bladder tumours and cell lines with 9q34 loss of heterozygosity (LOH) has identified five mutations in retained TSC1 alleles. Our results support the hypothesis that TSC1 can act as a bladder tumour suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353610     DOI: 10.1038/sj.onc.1202854

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.

Authors:  Christian Hafner; Agustí Toll; Alejandro Fernández-Casado; Julie Earl; Miriam Marqués; Francesco Acquadro; Marinela Méndez-Pertuz; Miguel Urioste; Núria Malats; Julie E Burns; Margaret A Knowles; Juan C Cigudosa; Arndt Hartmann; Thomas Vogt; Michael Landthaler; Ramón M Pujol; Francisco X Real
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

Review 2.  Molecular biology of bladder cancer.

Authors:  William Martin-Doyle; David J Kwiatkowski
Journal:  Hematol Oncol Clin North Am       Date:  2015-01-31       Impact factor: 3.722

Review 3.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

Review 4.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Authors:  Seth A Wander; Bryan T Hennessy; Joyce M Slingerland
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

5.  Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.

Authors:  Guangwu Guo; Xiaojuan Sun; Chao Chen; Song Wu; Peide Huang; Zesong Li; Michael Dean; Yi Huang; Wenlong Jia; Quan Zhou; Aifa Tang; Zuoquan Yang; Xianxin Li; Pengfei Song; Xiaokun Zhao; Rui Ye; Shiqiang Zhang; Zhao Lin; Mingfu Qi; Shengqing Wan; Liangfu Xie; Fan Fan; Michael L Nickerson; Xiangjun Zou; Xueda Hu; Li Xing; Zhaojie Lv; Hongbin Mei; Shengjie Gao; Chaozhao Liang; Zhibo Gao; Jingxiao Lu; Yuan Yu; Chunxiao Liu; Lin Li; Xiaodong Fang; Zhimao Jiang; Jie Yang; Cailing Li; Xin Zhao; Jing Chen; Fang Zhang; Yongqi Lai; Zheguang Lin; Fangjian Zhou; Hao Chen; Hsiao Chang Chan; Shirley Tsang; Dan Theodorescu; Yingrui Li; Xiuqing Zhang; Jian Wang; Huanming Yang; Yaoting Gui; Jun Wang; Zhiming Cai
Journal:  Nat Genet       Date:  2013-10-13       Impact factor: 38.330

Review 6.  Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise.

Authors:  Jaegil Kim; Rehan Akbani; Chad J Creighton; Seth P Lerner; John N Weinstein; Gad Getz; David J Kwiatkowski
Journal:  Clin Cancer Res       Date:  2015-10-15       Impact factor: 12.531

Review 7.  What we could do now: molecular pathology of bladder cancer.

Authors:  M A Knowles
Journal:  Mol Pathol       Date:  2001-08

Review 8.  Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.

Authors:  Margaret A Knowles; Fiona M Platt; Rebecca L Ross; Carolyn D Hurst
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

9.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12

10.  TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.

Authors:  M-C Liang; J Ma; L Chen; P Kozlowski; W Qin; D Li; J Goto; T Shimamura; D N Hayes; M Meyerson; D J Kwiatkowski; K-K Wong
Journal:  Oncogene       Date:  2009-12-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.